Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We have two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical stage of development. All of our drug candidates have been discovered and developed internally using our proprietary, unique chemical compound library and integrated discovery engine. We retain full ownership of all of our drug candidates. In 2012, we made significant progress with the development of our lead drug candidate, ganetespib, which is currently being evaluated in a broad range of trials including lung, breast, and other solid tumor and hematologic cancers. Over 20 clinical trials with ganetespib are ongoing, recently completed, or currently initiating. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.06 |
| Quarterly EPS Est: | -0.33 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
2 |
Data is provided by Zacks Investment Research
